# Tirzepatide: The Dual Incretin Record — Beta-Cell Function, Insulin Sensitivity, and What the Trials Measured

> Tirzepatide is the first approved dual GIP/GLP-1 receptor agonist. The SURPASS and SURMOUNT trials established its glycaemic and weight effects. An independent editorial record of the peer-reviewed literature.

The SURPASS and SURMOUNT programmes produced some of the most consequential glycaemic and weight-loss trial data of the decade. This site documents what they measured — with every quantitative claim cited.

## The short version

Tirzepatide is an FDA-approved medicine — approved for type 2 diabetes in May 2022, for obesity in November 2023, and for obstructive sleep apnea in adults with obesity shortly after. It is given as a once-weekly injection under the skin.

The drug is unusual because it activates two gut hormone receptors at once, not just one. Most drugs in this class activate only the GLP-1 receptor. Tirzepatide adds the GIP receptor — giving it a dual mechanism that produces larger effects on blood sugar and body weight than earlier drugs.

In the largest obesity trial (SURMOUNT-1, 2,539 adults), people at the highest dose lost an average of 20.9% of their body weight over 72 weeks. In a head-to-head trial against the main competitor drug (SURMOUNT-5, 751 adults), tirzepatide produced 20.2% weight loss versus 13.7% — a statistically significant difference [4, 5].

On the beta-cell and insulin sensitivity front — the particular lens this site covers — tirzepatide improved the disposition index (a combined measure of insulin secretion and insulin sensitivity) significantly more than the comparison drug in a dedicated mechanistic trial [8, 9].

What people report — including the downsides — is documented on [the effects page](/effects).

## What the Tirzepatide literature has established

Tirzepatide (INN: tirzepatide; also known as LY3298176) is a 39-amino-acid synthetic peptide that functions as a dual agonist of two incretin receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Incretin hormones are gut-derived signals released after eating that amplify insulin secretion in a glucose-dependent fashion — they work only when blood glucose is elevated, which is what gives this drug class its safety profile on blood sugar.

Tirzepatide is the first molecule to combine both incretin receptor targets in a single compound. In vitro signalling assays characterised it as an "imbalanced" dual agonist, engaging the GIP receptor to a greater degree than the GLP-1 receptor, and as a biased GLP-1 receptor agonist that favours cAMP generation over beta-arrestin recruitment [2]. These molecular properties are proposed to explain its unusually large effects on both glycaemia and body weight.

The compound's half-life of approximately five days — conferred by a C20 fatty diacid modification that allows it to bind albumin in the bloodstream — supports once-weekly dosing, a practical advantage for a chronic-use medicine [1].

In the SURPASS programme (type 2 diabetes, phase 3), Tirzepatide at 5, 10, and 15 mg once weekly reduced HbA1c (glycated haemoglobin — a three-month average of blood glucose) by 2.01, 2.24, and 2.30 percentage points respectively over 40 weeks. Those reductions were superior to semaglutide 1 mg at all three doses, with body weight reductions 1.9 to 5.5 kg greater [3].

In the SURMOUNT programme (obesity/overweight without diabetes), the headline finding at 72 weeks was a mean weight reduction of 20.9% at the 15 mg dose versus 3.1% with placebo [4]. In the head-to-head trial (SURMOUNT-5, n=751), tirzepatide reduced body weight by 20.2% versus 13.7% with the comparison drug over 72 weeks [5].

On the beta-cell and insulin sensitivity axis — the lens this site covers — a dedicated mechanistic trial by Heise et al. (Lancet Diabetes Endocrinol, 2022, n=117) measured the "disposition index": a combined readout of both insulin secretion rate and insulin sensitivity, assessed under a hyperinsulinaemic-euglycaemic clamp. Tirzepatide produced a disposition index estimated treatment difference (ETD) of 1.92 versus placebo (95% CI 1.59–2.24; p<0.0001) and 0.84 versus semaglutide (95% CI 0.46–1.21; p<0.0001), with greater improvements in both the insulin secretion rate (ETD 102.09 pmol/min/m²) and the M-value (insulin sensitivity, ETD 1.52 mg/min/kg) than the comparator [8].

Where tirzepatide goes from here spans obstructive sleep apnea (SURMOUNT-OSA), heart failure with preserved ejection fraction (SUMMIT), and metabolic dysfunction-associated steatohepatitis or MASH (SYNERGY-NASH). Each of those populations has now produced randomised trial data — a breadth of indication unusual for a drug at this stage of its development.

## Tirzepatide results: the key trial numbers

The quantitative record produced by the SURPASS and SURMOUNT programmes is unusually dense. The following is a structured reading of the principal findings.

**Type 2 diabetes (SURPASS-2, n=1879, 40 weeks):** HbA1c reduction of 2.30 percentage points at 15 mg once weekly. Body weight reduction treatment difference of 5.5 kg versus semaglutide 1 mg. Tirzepatide non-inferior and superior to semaglutide at all three doses tested [3].

**Obesity without diabetes (SURMOUNT-1, n=2539, 72 weeks):** Mean weight change of -15.0% (5 mg), -19.5% (10 mg), and -20.9% (15 mg) versus -3.1% for placebo. 96% of participants at the 15 mg dose achieved at least 5% weight reduction; 56% achieved at least 20% [4].

**Head-to-head obesity (SURMOUNT-5, n=751, 72 weeks):** Tirzepatide -20.2% versus the comparison drug -13.7% body weight. Greater reduction in waist circumference. Higher proportions reaching 10%, 15%, 20%, and 25% weight-loss thresholds [5].

**Mechanistic (Heise 2022, n=117, 28 weeks):** Clamp disposition index ETD 1.92 versus placebo; ETD 0.84 versus semaglutide — the most direct evidence that tirzepatide improves beta-cell function and insulin sensitivity more than selective GLP-1 receptor agonism [8].

**Tirzepatide reviews — what early-response data shows:** A pooled SURPASS post-hoc analysis found that an early fasting-glucose response (≥20% reduction at week 4) or an early weight response (≥5% at week 8) predicted better long-term HbA1c and metabolic outcomes. Even participants without early response still achieved clinically meaningful glycaemic and weight reductions [11].

For further analysis, [Tirzepatide research](/research) organises the full trial record by mechanism and indication.

## Tirzepatide peptide: the molecular structure behind the dual action

Tirzepatide is a tirzepatide peptide — a synthetic 39-amino-acid molecule built on the native GIP sequence backbone with structural modifications that confer dual receptor activity and long half-life. The GIP-based scaffold is conjugated via a glutamic acid linker and two (2-(2-aminoethoxy)ethoxy)acetic acid units to a C20 fatty diacid (eicosanedioic acid) moiety attached to a lysine side chain. That fatty-diacid arm enables reversible binding to albumin in the bloodstream, extending the compound's half-life to approximately five days and permitting once-weekly subcutaneous dosing [1].

Molecular weight is 4813.53 Da. Molecular formula: C225H348N48O68. CAS number: 2023788-19-2. ATC code: A10BX16.

In receptor assays, the molecule engages the GIP receptor to a greater degree than the GLP-1 receptor, and at the GLP-1 receptor it is a biased agonist favouring cAMP signalling over beta-arrestin recruitment [2]. Beta-arrestin recruitment typically promotes receptor internalisation; reduced internalisation means more prolonged GLP-1R surface engagement. Both mechanisms are proposed to contribute to the molecule's performance in clinical trials compared with selective GLP-1 receptor agonism alone.

For a detailed walkthrough of each receptor pathway, see the [tirzepatide mechanism of action](/mechanism-of-action) page.

## Tirzepatide injection: administration in the clinical trial programme

In every phase 3 trial, tirzepatide was administered as a subcutaneous injection — the only route studied. Injections were delivered once weekly into the abdomen, thigh, or upper arm.

The approved stepwise titration schedule starts at 2.5 mg once weekly for four weeks, escalating by 2.5 mg every four weeks, with a maximum maintenance dose of 15 mg once weekly. The three maintenance doses studied in phase 3 — 5 mg, 10 mg, and 15 mg — are separated by dose-finding steps to allow tolerability to develop before the dose increases.

Gastrointestinal adverse events (nausea, vomiting, diarrhoea, constipation) were the most common adverse effects across the trial programme and were dose-related, most frequent during dose escalation and generally attenuating with continued exposure [6, 13, 14]. The stepwise titration schedule is designed to manage this burden.

---

An independent editorial record of what the SURPASS and SURMOUNT trials — and the mechanistic studies behind them — actually measured.